On 9/16/24, Biomarin Pharmaceutical Inc (NASDAQ: BMRN) stock suffered a major decline of -17.7%, closing at $69.86. Moreover, this decline was accompanied by exceptionally high trading volume at 624% of normal. The stock has been weak relative to the market over the last nine months and has declined -16.9% during the last week.
Current PriceTarget Research Rating
BMRN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
Biomarin Pharmaceutical has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Biomarin Pharmaceutical has a neutral Power Rating of 45 and a slightly negative Appreciation Score of 40, with the Negative Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment